Stockscreener 앱 받기
14.25
0.14%
0.02
시간 외 거래:
14.25
전일 마감가:
$14.23
열려 있는:
$14.25
하루 거래량:
70,222
Relative Volume:
0.33
시가총액:
$533.53M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-1.99%
1개월 성능:
+22.53%
6개월 성능:
+16.90%
1년 성능:
+0.00%
1일 변동 폭
$13.70
$14.35
1주일 범위
$13.43
$15.61
52주 변동 폭
$5.485
$31.13
Oruka Therapeutics Inc Stock (ORKA) Company Profile
명칭
Oruka Therapeutics Inc
전화
650-606-7910
주소
855 OAK GROVE AVE., MENLO PARK
ORKA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ORKA
Oruka Therapeutics Inc
|
14.25 | 532.78M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Oruka Therapeutics Inc Stock (ORKA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-22 | 개시 | BTIG Research | Buy |
| 2025-02-04 | 개시 | Wolfe Research | Outperform |
| 2024-10-11 | 개시 | Stifel | Buy |
| 2024-10-07 | 개시 | H.C. Wainwright | Buy |
| 2024-09-17 | 개시 | Leerink Partners | Outperform |
| 2024-09-16 | 개시 | TD Cowen | Buy |
| 2024-09-13 | 개시 | Jefferies | Buy |
| 2018-02-27 | 개시 | Ascendiant Capital Markets | Buy |
| 2013-10-09 | 개시 | Dawson James | Buy |
모두보기
Oruka Therapeutics Inc 주식(ORKA)의 최신 뉴스
What is the risk reward ratio of investing in Oruka Therapeutics Inc. stockStay ahead with advanced stock screening tools - jammulinksnews.com
What makes Oruka Therapeutics Inc. stock price move sharplyUnlock expert stock analysis and alerts - jammulinksnews.com
What are the latest earnings results for Oruka Therapeutics Inc.Rapid-fire capital growth - jammulinksnews.com
What institutional investors are buying Oruka Therapeutics Inc. stockAchieve breakthrough performance in the market - jammulinksnews.com
How volatile is Oruka Therapeutics Inc. stock compared to the marketDouble-digit growth - jammulinksnews.com
Why Oruka Therapeutics Inc. stock attracts strong analyst attentionFree Investment Risk Control - Newser
How does Oruka Therapeutics Inc. compare to its industry peersTriple-digit return opportunities - jammulinksnews.com
How high can Oruka Therapeutics Inc. stock price go in 2025Free Stock Market Strategy Classes - Newser
What analysts say about Oruka Therapeutics Inc. stockBreakthrough financial growth - PrintWeekIndia
What drives Oruka Therapeutics Inc. stock priceLightning-fast capital gains - Autocar Professional
printweek> 2025> Oruka Therapeutics Inc. Stock Analysis and ForecastBreakthrough profits - PrintWeekIndia
Is Oruka Therapeutics Inc. a good long term investmentExtraordinary performance - PrintWeekIndia
H.C. Wainwright reiterates Buy rating on Oruka Therapeutics stock as FDA clears IND - Investing.com Canada
Oruka Therapeutics: Promising Pipeline and Strategic Advancements Drive Buy Rating - TipRanks
Strong Buy Recommendation for Oruka Therapeutics: Promising Pipeline and Attractive Valuation - TipRanks
Oruka Therapeutics Shares Climb After FDA Greenlights Psoriasis Drug Trial - MSN
Oruka Therapeutics Inc. Stock Analysis and ForecastMassive profits - Autocar Professional
Wedbush Reiterates Outperform Rating for Oruka Therapeutics (NASDAQ:ORKA) - Defense World
Oruka Therapeutics Announces IND Clearance for EVERLAST-A - GlobeNewswire
Oruka Therapeutics stock rises after FDA clears IND for psoriasis drug - Investing.com India
Stifel reiterates Buy rating on Oruka Therapeutics stock with $47 target - Investing.com Canada
Oruka Therapeutics: Revolutionizing Psoriasis Treatment with Extended-Dosing Biologics - AInvest
FDA clears Oruka’s IND for psoriasis drug ORKA-001 phase 2a trial - Investing.com
Oruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in September - Yahoo Finance
Oruka Therapeutics Inc (ORKA) 재무 분석
Oruka Therapeutics Inc (ORKA)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Oruka Therapeutics Inc 주식 (ORKA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Venrock Healthcare Capital Par | 10% Owner |
Feb 13 '25 |
Buy |
11.63 |
14,950 |
173,868 |
4,059,634 |
| Venrock Healthcare Capital Par | 10% Owner |
Feb 12 '25 |
Buy |
11.86 |
8,971 |
106,396 |
4,044,684 |
| Venrock Healthcare Capital Par | 10% Owner |
Feb 11 '25 |
Buy |
10.95 |
9,593 |
105,043 |
4,035,713 |
| Venrock Healthcare Capital Par | 10% Owner |
Feb 10 '25 |
Buy |
10.90 |
574 |
6,257 |
4,026,120 |
| JANUS HENDERSON GROUP PLC | 10% Owner |
Aug 16 '24 |
Buy |
2.93 |
5,818 |
17,067 |
2,117,213 |
0.97%
0.22%
자본화:
|
볼륨(24시간):